Clinical trials: Resistance Associated Substitutions
Hepatitis C, Public Health
HCV RAS Testing in Public Health Programs
Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation.
- Conditions
- Hepatitis C, Public Health, Direct Acting Antiviral Agents, Resistance Associated Substitutions
- Trial name
- RAS-HCV (NCT04242433)
- Testing
- Direct Acting Antivirals
- Where
- 2 sites in India
- Volunteers
- 200 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh